Once again, this varies based on weight loss goals and the rate of weight loss which is impacted by multiple factors
Further RCT-based studies are not currently feasible
PubMed Phase-III trials on Tesamorelin showed 8 % visceral-fat reduction in 69 % of users versus 33 % on placebo
A GP or specialist can assess whether an individual's medical history, current medications, or underlying conditions make the use of a GLP-1/GIP/glucagon receptor agonist particularly risky
Continue reading After 6 months of treatment, use of GLP-1 medications was associated with: Increased risk of androgenic alopecia Increased risk of non-scarring hair loss No significant change to the risk of telogen effluvium No significant change to the risk of alopecia areata After 12 months of treatment, use of GLP-1 medications was associated with: Increased risk of androgenic alopecia Increased risk of non-scarring hair loss Increased risk of telogen effluvium No significant change to the risk of alopecia areata Interestingly, no increased risk of alopecia areata was found, given that GLP-1 medications like semaglutide have been reported to be linked to this condition in case studies
Semaglutide and tirzepatide medications have changed the treatment for obesity and diabetes